INCREASE OF THE IN VITRO COMPLEMENT-DEPENDENT CYTOTOXICITY AGAINST AUTOLOGOUS INVASIVE HUMAN BLADDER TUMOR CELLS BY NEURAMINIDASE TREATMENT
| Autor: | Flemming Jacobsen |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Cytotoxicity Immunologic Male Immunology Neuraminidase Tumor cells Biology Agammaglobulinemia Physical Stimulation medicine Humans Cytotoxicity Aged Neoplasm Staging Urinary bladder General Immunology and Microbiology Complement System Proteins General Medicine Complement C2 Middle Aged Molecular biology In vitro Complement-dependent cytotoxicity Complement system Cytolysis Cell Transformation Neoplastic medicine.anatomical_structure Urinary Bladder Neoplasms biology.protein Female |
| Zdroj: | Acta Pathologica Microbiologica Scandinavica Series C: Immunology. :187-192 |
| ISSN: | 0108-0202 |
| DOI: | 10.1111/j.1699-0463.1982.tb01437.x |
| Popis: | Complement-dependent cytotoxicity (CDC) was measured in a 51-Cr release assay against tumor cells from 13 non-invasive and 7 invasive transitional-cell tumors of the urinary bladder. CDC was compared between mechanically dispersed tumor cells and neuraminidase-treated tumor cells. Neuraminidase treatment of bladder tumor cells enhanced their susceptibility to complement-dependent cytolysis. There were no differences in CDC between autologous and allogenic sera. Mechanically dispersed tumor cells showed no significant differences in susceptibility when non-invasive and invasive tumor cells were compared, whereas significant differences in CDC were seen when neuraminidase-treated non-invasive and invasive tumor cells were used as targets. A C2 deficient serum showed significantly reduced cytotoxicity suggesting that the CDC reaction requires classical complement activation. A hypogammaglobulinemic serum showed stronger CDC compared to autologous and other allogenic sera and upon dilution of autologous sera and hypogammaglobulinemic serum CDC declined parallelly. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|